Related Experiment Video

Updated: May 31, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents

B Lallemand1, M Gelbcke, J Dubois

  • 1Laboratoire de Chimie BioAnalytique, Toxicologie et Chimie Physique Appliquée, Université Libre de Bruxelles, Brussels, Belgium.

Mini Reviews in Medicinal Chemistry
|July 19, 2011
PubMed

Insights

Glycyrrhetinic acid (GA) derivatives show promise for treating cancers resistant to standard therapies. These compounds target key cancer cell proteins unrelated to multidrug resistance or apoptosis evasion, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cancer treatment faces challenges due to multidrug resistance (MDR) and apoptosis resistance, impacting approximately 50% of adult solid cancers and even more in pediatric cases.
  • Existing kinase inhibitors and targeted therapies are often ineffective against these resistant cancer phenotypes.
  • Glycyrrhetinic acid (GA) and its derivatives present a potential strategy to overcome treatment resistance.

Purpose of the Study:

  • To investigate the potential of Glycyrrhetinic acid (GA) derivatives in overcoming cancer cell resistance.
  • To explore GA derivatives' mechanisms of action against cancer types with poor prognoses.
  • To identify novel therapeutic targets beyond MDR and apoptosis pathways.

Main Methods:

  • The study focuses on the biological activity of GA derivatives.
  • Investigates the interaction of GA derivatives with specific cellular targets.
  • Examines the role of proteasome and peroxisome proliferator-activated receptors (PPARs) in cancer cell biology.

Main Results:

  • Some GA derivatives demonstrate the ability to target both the proteasome and PPARs.
  • These targeted proteins are crucial in cancer cell biology.
  • The targeted pathways are distinct from those involved in MDR and apoptosis resistance.

Conclusions:

  • GA derivatives offer a promising new approach for treating resistant cancers.
  • Targeting the proteasome and PPARs represents a novel strategy for cancer therapy.
  • Further research into GA derivatives could lead to improved cancer treatment outcomes for patients with poor prognoses.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...